This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
healthcare: Archive
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
by Urmimala Biswas
Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.
ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices
UnitedHealth Jumps 12% in a Month: But is it Healthy Enough to Buy?
by Kaibalya Pravo Dey
UNH surges 12% in a month, but with rising costs and regulatory pressures, is now the time to buy or wait?
UNHPositive Net Change BRK.BNegative Net Change HUMPositive Net Change ELVNegative Net Change
healthcare hmo insurance medical
UnitedHealth vs. Molina: Who's Poised for the Healthiest Comeback?
by Kaibalya Pravo Dey
Health insurers are facing turbulence, but which stock is set to rebound stronger: the diversified giant UNH or Medicaid-focused MOH?
UNHPositive Net Change BRK.BNegative Net Change MOHNegative Net Change
healthcare hmo insurance medical
UnitedHealth Reaffirms 2025 EPS Guidance: Time to Buy or Wait?
by Kaibalya Pravo Dey
UNH reaffirms its 2025 EPS outlook, but mounting costs, legal probes and valuation pressures cloud the path ahead.
UNHPositive Net Change BRK.BNegative Net Change MOHNegative Net Change CNCPositive Net Change
earnings-outlook healthcare hmo insurance medical
Investing in the Age of Longevity: Silver Economy Stocks in Focus
by Urmimala Biswas
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
ABTNegative Net Change AMGNNegative Net Change MDTNegative Net Change SYKNegative Net Change DXCMPositive Net Change ABBVNegative Net Change
biotechnology biotechs healthcare medical medical-devices robotics
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?
by Urmimala Biswas
BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.
AZNNegative Net Change NVDANegative Net Change BFLYNegative Net Change TEMNegative Net Change
artificial-intelligence earnings-outlook earnings-report earnings-surprise healthcare medical medical-devices smart-health
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
by Urmimala Biswas
Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.
IRTCNegative Net Change SOPHPositive Net Change TEMNegative Net Change
artificial-intelligence earnings-outlook earnings-report earnings-surprise healthcare medical medical-devices
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline
by Kaibalya Pravo Dey
ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.
UNHPositive Net Change CNCPositive Net Change ELVNegative Net Change
earnings-outlook healthcare hmo insurance insurance-premium medical
Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?
by Urmimala Biswas
CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.
UNHPositive Net Change CVSPositive Net Change HLFPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-surprise healthcare medical medical-devices
UnitedHealth Crashing After Q2 Shock: Should You Panic or Pounce?
by Kaibalya Pravo Dey
UNH plunges 12.9% after weak Q2 and slashing 2025 EPS guidance, sparking fears of deeper structural issues ahead.
UNHPositive Net Change MOHNegative Net Change CNCPositive Net Change
earnings-outlook earnings-surprise healthcare hmo insurance medical
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Urmimala Biswas
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
AZNNegative Net Change TXGNegative Net Change SOPHPositive Net Change TEMNegative Net Change
artificial-intelligence earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices smart-health
Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
by Urmimala Biswas
Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.
AZNNegative Net Change NVONegative Net Change NVDANegative Net Change TEMNegative Net Change
artificial-intelligence healthcare medical medical-devices smart-health tech-stocks
CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?
by Urmimala Biswas
CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.
UNHPositive Net Change CVSPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report healthcare medical medical-devices retail
UnitedHealthcare Pressure Builds: Trouble Ahead for UNH's Q2 Earnings?
by Kaibalya Pravo Dey
UNH braces for a steep Q2 profit drop as soaring medical costs and DOJ scrutiny shake investor confidence.
UNHPositive Net Change HUMPositive Net Change MOHNegative Net Change
earnings-outlook earnings-preview healthcare hmo insurance insurance-premium medical
UnitedHealth on Thin Ice Before Q2 Earnings: Should Investors Exit?
by Kaibalya Pravo Dey
UNH braces for a 27% earnings drop in Q2 as soaring medical costs, margin pressure and investor jitters weigh on performance.
UNHPositive Net Change HUMPositive Net Change MOHNegative Net Change
earnings-outlook earnings-preview healthcare hmo insurance insurance-premium medical
CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?
by Urmimala Biswas
Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.
UNHPositive Net Change CVSPositive Net Change HLFPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices retail
TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?
by Urmimala Biswas
TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.
AZNNegative Net Change IRTCNegative Net Change SOPHPositive Net Change TEMNegative Net Change
artificial-intelligence healthcare medical medical-devices
CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?
by Urmimala Biswas
CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.
UNHPositive Net Change CIPositive Net Change CVSPositive Net Change
healthcare medical retail smart-health
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
ABTNegative Net Change RHHBYNegative Net Change NVONegative Net Change MDTNegative Net Change SYKNegative Net Change EWPositive Net Change
healthcare medical medical-devices pharmaceuticals
These Top 4 Women-Run Company Stocks Are Quietly Beating the Market
by Shrabana Mukherjee
These women-run company stocks offer high growth and stability.
ACNPositive Net Change MCKNegative Net Change ELNegative Net Change ADBEPositive Net Change CNCPositive Net Change BMBLNegative Net Change
healthcare internet medical medical-devices tech-stocks thematic
CVS vs. Amazon: Healthcare Battle Continues- Which Stock to Buy Now?
by Urmimala Biswas
CVS surges with a 56% YTD return and an integrated care model, as AMZN bets on tech and logistics to reshape healthcare.
AMZNPositive Net Change CVSPositive Net Change
healthcare medical retail smart-health
BTSG vs. OPCH: Which Home Infusion Stock is a Better Buy Now?
by Urmimala Biswas
BTSG surges with 33% infusion growth and stronger EPS gains, making it a more compelling pick than OPCH right now.
OPCHNegative Net Change PLTRNegative Net Change BTSGPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-report healthcare hospitals medical smart-health
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
by Urmimala Biswas
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
AZNNegative Net Change GHNegative Net Change TEMNegative Net Change
artificial-intelligence biotechnology cancer earnings-outlook healthcare medical
CVS Surges on Regulatory Relief, Medicare Advantage Push: Time to Buy?
by Urmimala Biswas
CVS surges 53.7% YTD as regulatory relief, strong execution and Medicare Advantage momentum fuel investor confidence.
CVSPositive Net Change HLFPositive Net Change
earnings-outlook healthcare medical retail
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
VRTXPositive Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs cancer crispr gene-editing gene-therapy healthcare medical